Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 11/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.45 |
| ▸ | RORA | P35398 | 1/20 | 0.44 |
| ▸ | RORB | Q92753 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938383 | 0.96 | PTGER4 (0.56) | PTGER4CNR2RORCRORARORB | |
| SCHEMBL4779304 | 0.93 | PTGER4 (0.54) | PTGER4CNR2RORCRORARORB | |
| SCHEMBL28182546 | 0.90 | PTGER4 (0.51) | PTGER4CNR2RORCRORARORB | |
| SCHEMBL4840158 | 0.84 | DHFR (0.60) | PTGER4CNR2KDM4EPOLBPKM | |
| SCHEMBL5795412 | 0.81 | CYP1A2 (0.54) | PTGER4CNR2RORCRORARORB | |
| SCHEMBL11829790 | 0.79 | PTGER4 (0.72) | PTGER4CNR2KDM4EPOLBPKM | |
| SCHEMBL22166435 | 0.79 | PTGER4 (0.63) | PTGER4KDM4EPOLBPKMHTT | |
| SCHEMBL416844 | 0.79 | PTGER4 (0.70) | PTGER4KDM4EPOLBPKMHTT | |
| SCHEMBL29507657 | 0.79 | PTGER4 (0.70) | PTGER4KDM4EPOLBPKMHTT | |
| SCHEMBL19179039 | 0.78 | CYP1A2 (0.50) | PTGER4CNR2RORCNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| EP-2928884-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| EP-2928884-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-14 | — | — | EP | disclosed |
| CN-104854098-A | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG | 2015-08-19 | — | — | CN | disclosed |
| WO-2014086739-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-12 | — | — | WO | disclosed |
| WO-2006012310-A2 | CARBAZOLE DERIVATIVES FOR TREATING POLYCYSTIC KIDNEY DISEASE | GENZYME CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885CNR2 121/4885RORC 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.